Ep. 243 - Radiopharma Alpha Emitters, AZ’s Galbraith and LNPs

Alpha emitters are the latest trend in the hot radioligand space, but there’s debate about which isotope offers the best attributes for optimizing safety and efficacy. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the benefits and challenges that come with developing radiopharmaceuticals using lead-212 versus its more well-known counterpart actinium-225. They also discuss Editor-in-Chief Simone Fishburn’s conversation with Susan Galbraith, EVP of Oncology R&D at AstraZeneca, the latest innovations in delivering lipid nanoparticles to specific tissues beyond the liver, and the most recent oral GLP-1 obesity data from Roche.View full story: https://www.biocentury.com/article/65300800:00 - Intro05:36 - Radiopharma Alpha Emitters12:18 - AZ’s Susan Galbraith21:40 - Lipid Nanoparticles25:22 - Oral GLP-1 RaceReach us by sending a text

There are no comments yet.

Please log in to write the first comment.